TREATMENT OF PROSTATE CANCER WITH HIFU THERAPY: PERIOPERATIVE PATIENT MANAGEMENT AND EARLY RESULTS
https://doi.org/10.17238/issn2072-3180.2021.2.49-54
Abstract
Objective. High-intensity ultrasound ablation (HIFU-therapy) of the prostate gland is a young but promising treatment method. For the most effective and safe therapy, it is necessary to determine the indications for its implementation by analyzing the available results.
Materials and methods. The experience of treating 55 patients with localized prostate cancer is presented. The average age is 67.6±13 L, preoperative total PSA level of blood 8.341, the Gleason grade of acinar adenocarcinoma is 4-6 scores, the gland volume according to MRI is 34±20.7 cm3, the PIRADSv2-4 score is used.
Results. Intraoperative complications were not recorded in any case. The number and severity of postoperative complications (acute urinary retention, stricture of the prostatic urethra, accession of lower urinary tract infections, grade I-II urinary incontinence) corresponded to the data of the world literature. The postoperative total PSA index of blood within 12 months decreased by 84.58%
Conclusion. HIFU-therapy is a promising and relatively safe method for treating prostate cancer with a minimum number of possible intraoperative complications. Given the low percentage of relapses of the disease, it can be concluded that the criteria for selecting patients are correct. For the formation of the complete characteristics of the method, indications and contraindications to it, it is necessary to carry out further studies.
About the Authors
K. V. Stegniy
FEFU Medical Center
Russian Federation
Russian Federation
Stegniy Kirill Vladimirovich - Corresponding Member, Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Director
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
B. Yu. Siunov
FEFU Medical Center
Russian Federation
Russian Federation
Siunov Bogdan Yurievich - urologist
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10
A. V. Grebneva
FEFU Medical Center
Russian Federation
Russian Federation
Grebneva Anastasia Viktorovna - urologist
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
S. V. Proniagin
FEFU Medical Center
Russian Federation
Russian Federation
Proniagin Sergey Viktorovich - urologist
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
R. A. Goncharuk
FEFU Medical Center
Russian Federation
Russian Federation
Goncharuk Roman Anatolyevich - PhD in Medical sciences, surgeon
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
E. R. Dvoinikova
FEFU Medical Center
Russian Federation
Russian Federation
Dvoinikova Ekaterina Romanovna - PhD in Medical sciences, deputy Director
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
A. A. Krekoten
FEFU Medical Center
Russian Federation
Russian Federation
Krekoten Alexander Anatolevich - PhD in Medical sciences, surgeon
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
D. Yu. Kondratenko
FEFU Medical Center
Russian Federation
Russian Federation
Kondratenko Dina Yurievna - urologist
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
I. I. Molchan
FEFU Medical Center
Russian Federation
Russian Federation
Molchan Ilya Ivanovich - urologist
Primorsky Territory, Vladivostok, Russian Island, p. Ajax, 10, 690922
References
1. Aksel E.M., Matveev V.B. Statistika zlokachestvennyh novoobrazovanij mochevyh i muzhskih polovyh organov v Rossii i stranah byvshego SSSR [Statistics of malignant neoplasms of the urinary and male genital organs in Russia and the countries of the former USSR]. Oncourology, 2019, 15 (2), pp. 15–24. (In Russ.)
2. Kaprin A.D., Starinskiy V.V., Shakhzadova A. О. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2019 godu [The state of cancer care for the population of Russia in 2019]. M.: Moscow Research Institute of the Oncology. P.A. Herzen – branch of the Federal State Budgetary Institution “National Medical Research Center of Radiology” of the Ministry of Health of Russia, 2020. 239 p. ISBN 978-5-85502-255-1 (In Russ.)
3. Kovalenko R.Yu., Zhuravlev V.N. Maloinvazivnye metody lecheniya lokalizovannyh form raka predstatel’noj zhelezy. Blizhajshie i otdalennye oslozhneniya [Minimally invasive methods of treatment of localized forms of prostate cancer. Immediate and late complications]. Urology, 2017, 2 (146), pp. 52 – 54.
4. Shestaev A.Yu., Protoschak V.V. Vybor metoda drenirovaniya mochevogo puzyrya pri HIFU-terapii raka predstatel’noj zhelezy [The choice of the method of urinary bladder drainage in HIFU-therapy of prostate cancer]. Experimental and Clinical Urology, 2014, 2, pp. 32–33.
5. Chapelon J.Y., Margonari J. Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol., 1992, № 22(2), рр. 147–152.
6. Gelet A., Chapelon J.Y. Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. Endourol., 1993, Jun.; 7(3), рр. 249–253.
7. Guillaumier S., Peters M., Arya M. et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur. Urol., 2018, 74(4), рр. 422–429. https://doi.org/10.1016/j.eururo.2018.06.006
8. Kincaide L.F., Sanghvi N.T. Noninvasive ultrasonic subtotal ablation of the prostate in dogs; Am. J. Vet. Res., 1996, Aug.; 57(8), рр. 1225–1227.
9. Madersbacher S., Kratzik C. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound; J. Urol., 1994, Dec.; 152(6 Pt. 1), рр. 1956–1960; discussion 1960–1961.
10. Madersbacher S., Pedevilla M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo; Cancer Res., 1995, Aug. 1; 55(15), рр. 3346–3351.
11. Yue He., Ping Tan et al. The primary treatment of prostate cancer with high-intensity focused ultrasound: A systematic review and metaanalysis Medicine (Baltimore), 2020, Oct. 9, 99(41), рр. 22610. https://doi.org/10.1097/MD.0000000000022610
12. Ziglioli F., Baciarello M. et al. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. Ann Med Surg (Lond), 2020, May 30; 56, рр. 110–115. https://doi.org/10.1016/j.amsu.2020.05.029
Review
For citations:
Stegniy K.V., Siunov B.Yu., Grebneva A.V., Proniagin S.V., Goncharuk R.A., Dvoinikova E.R., Krekoten A.A., Kondratenko D.Yu., Molchan I.I. TREATMENT OF PROSTATE CANCER WITH HIFU THERAPY: PERIOPERATIVE PATIENT MANAGEMENT AND EARLY RESULTS. Moscow Surgical Journal. 2021;(2):49-54. (In Russ.) https://doi.org/10.17238/issn2072-3180.2021.2.49-54
Views:
638
Email this article 